These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 12388670)
61. Effects of 2-deoxy-D-glucose on methamphetamine-induced dopamine and serotonin neurotoxicity. Callahan B; Yuan J; Stover G; Hatzidimitriou G; Ricaurte G J Neurochem; 1998 Jan; 70(1):190-7. PubMed ID: 9422362 [TBL] [Abstract][Full Text] [Related]
62. 3,4-Methylenedioxymethamphetamine induces monoamine release, but not toxicity, when administered centrally at a concentration occurring following a peripherally injected neurotoxic dose. Esteban B; O'Shea E; Camarero J; Sanchez V; Green AR; Colado MI Psychopharmacology (Berl); 2001 Mar; 154(3):251-60. PubMed ID: 11351932 [TBL] [Abstract][Full Text] [Related]
63. The effects of co-administration of 3,4-methylenedioxymethamphetamine ("ecstasy") or para-methoxyamphetamine and moclobemide at elevated ambient temperatures on striatal 5-HT, body temperature and behavior in rats. Stanley N; Salem A; Irvine RJ Neuroscience; 2007 Apr; 146(1):321-9. PubMed ID: 17306465 [TBL] [Abstract][Full Text] [Related]
64. Comparison of (+)-methamphetamine, ±-methylenedioxymethamphetamine, (+)-amphetamine and ±-fenfluramine in rats on egocentric learning in the Cincinnati water maze. Vorhees CV; He E; Skelton MR; Graham DL; Schaefer TL; Grace CE; Braun AA; Amos-Kroohs R; Williams MT Synapse; 2011 May; 65(5):368-78. PubMed ID: 20730798 [TBL] [Abstract][Full Text] [Related]
65. Neurotoxic effects of +/-fenfluramine and phenteramine, alone and in combination, on monoamine neurons in the mouse brain. McCann UD; Yuan J; Ricaurte GA Synapse; 1998 Nov; 30(3):239-46. PubMed ID: 9776127 [TBL] [Abstract][Full Text] [Related]
66. Evaluation of the neurotoxicity of N-methyl-1-(4-methoxyphenyl)-2-aminopropane (para-methoxymethamphetamine, PMMA). Steele TD; Katz JL; Ricaurte GA Brain Res; 1992 Sep; 589(2):349-52. PubMed ID: 1382813 [TBL] [Abstract][Full Text] [Related]
67. 3,4-Methylenedioxymethamphetamine increases interleukin-1beta levels and activates microglia in rat brain: studies on the relationship with acute hyperthermia and 5-HT depletion. Orio L; O'Shea E; Sanchez V; Pradillo JM; Escobedo I; Camarero J; Moro MA; Green AR; Colado MI J Neurochem; 2004 Jun; 89(6):1445-53. PubMed ID: 15189347 [TBL] [Abstract][Full Text] [Related]
68. Long-lasting behavioral sensitization to psychostimulants following p-chloroamphetamine-induced neurotoxicity in mice. Itzhak Y; Achat-Mendes CN; Ali SF; Anderson KL Neuropharmacology; 2004 Jan; 46(1):74-84. PubMed ID: 14654099 [TBL] [Abstract][Full Text] [Related]
69. The mechanisms involved in the long-lasting neuroprotective effect of fluoxetine against MDMA ('ecstasy')-induced degeneration of 5-HT nerve endings in rat brain. Sanchez V; Camarero J; Esteban B; Peter MJ; Green AR; Colado MI Br J Pharmacol; 2001 Sep; 134(1):46-57. PubMed ID: 11522596 [TBL] [Abstract][Full Text] [Related]
70. Role of 5-HT₂C receptors in effects of monoamine releasers on intracranial self-stimulation in rats. Bauer CT; Banks ML; Blough BE; Negus SS Psychopharmacology (Berl); 2015 Sep; 232(17):3249-58. PubMed ID: 26041338 [TBL] [Abstract][Full Text] [Related]
71. Causes and consequences of the loss of serotonergic presynapses elicited by the consumption of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") and its congeners. Huether G; Zhou D; Rüther E J Neural Transm (Vienna); 1997; 104(8-9):771-94. PubMed ID: 9451711 [TBL] [Abstract][Full Text] [Related]
72. p-Chloroamphetamine (PCA), 3,4-methylenedioxy-methamphetamine (MDMA) and d-fenfluramine pretreatment attenuates d-fenfluramine-evoked release of 5-HT in vivo. Series HG; Cowen PJ; Sharp T Psychopharmacology (Berl); 1994 Dec; 116(4):508-14. PubMed ID: 7535469 [TBL] [Abstract][Full Text] [Related]
73. In vivo analysis of serotonin clearance in rat hippocampus reveals that repeated administration of p-methoxyamphetamine (PMA), but not 3,4-methylenedioxymethamphetamine (MDMA), leads to long-lasting deficits in serotonin transporter function. Callaghan PD; Owens WA; Javors MA; Sanchez TA; Jones DJ; Irvine RJ; Daws LC J Neurochem; 2007 Feb; 100(3):617-27. PubMed ID: 17181558 [TBL] [Abstract][Full Text] [Related]
74. The hyperthermic and neurotoxic effects of 'Ecstasy' (MDMA) and 3,4 methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype. Colado MI; Williams JL; Green AR Br J Pharmacol; 1995 Aug; 115(7):1281-9. PubMed ID: 7582557 [TBL] [Abstract][Full Text] [Related]
75. MDMA (ecstasy) inhibition of MAO type A and type B: comparisons with fenfluramine and fluoxetine (Prozac). Leonardi ET; Azmitia EC Neuropsychopharmacology; 1994 Jul; 10(4):231-8. PubMed ID: 7945733 [TBL] [Abstract][Full Text] [Related]
76. Pharmacological characterization of ecstasy synthesis byproducts with recombinant human monoamine transporters. Pifl C; Nagy G; Berényi S; Kattinger A; Reither H; Antus S J Pharmacol Exp Ther; 2005 Jul; 314(1):346-54. PubMed ID: 15831439 [TBL] [Abstract][Full Text] [Related]
77. A study of the mechanism of MDMA ('ecstasy')-induced neurotoxicity of 5-HT neurones using chlormethiazole, dizocilpine and other protective compounds. Colado MI; Green AR Br J Pharmacol; 1994 Jan; 111(1):131-6. PubMed ID: 7516800 [TBL] [Abstract][Full Text] [Related]
78. Comparative effects of substituted amphetamines (PMA, MDMA, and METH) on monoamines in rat caudate: a microdialysis study. Gough B; Imam SZ; Blough B; Slikker W; Ali SF Ann N Y Acad Sci; 2002 Jun; 965():410-20. PubMed ID: 12105116 [TBL] [Abstract][Full Text] [Related]
79. In vivo correlates of central serotonin function after high-dose fenfluramine administration. Baumann MH; Ayestas MA; Rothman RB Ann N Y Acad Sci; 1998 May; 844():138-52. PubMed ID: 9668672 [TBL] [Abstract][Full Text] [Related]
80. Thioether metabolites of 3,4-methylenedioxyamphetamine and 3,4-methylenedioxymethamphetamine inhibit human serotonin transporter (hSERT) function and simultaneously stimulate dopamine uptake into hSERT-expressing SK-N-MC cells. Jones DC; Lau SS; Monks TJ J Pharmacol Exp Ther; 2004 Oct; 311(1):298-306. PubMed ID: 15169827 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]